Indeed, the area of hypoxia was significantly increased (Fig. 7a) and the CXCL12 expression was confirmed to be significantly upregulated in the bevacizumab-treated Y-MESO-14 tumours compared with the control tumours (Fig. 7b, left panel). The gene discussed is CXCL12; the disease is neoplasm.